ArticleEuropean radiology2025
Lipoprotein(a) associates with high-resolution MRI-assessed intracranial plaque vulnerability and long-term stroke recurrence.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesLipoprotein(a) [Lp(a)] was related to increased risk of major adverse cardiovascular events. We aimed to explore the association between Lp(a) levels and intracranial plaque vulnerable features identified through high-resolution magnetic resonance imaging (HRMRI), along with their prognostic significance. MATERIALS AND
methodsA total of 210 consecutive patients with symptomatic intracranial atherosclerosis stenosis (sICAS) who underwent Lp(a) measurement and HRMRI were retrospectively collected. Plaque vulnerable features were defined as intraplaque hemorrhage (IPH), positive remodeling, plaque surface irregularity, and grade 2 plaque enhancement. Binary classification of Lp(a) levels was applied to assess its relationships with plaque features and long-term stroke recurrence using Cox proportional hazard models.
resultsPatients with a high Lp(a) level had a higher presence of IPH (30.59% versus 52.50%, p = 0.01), surface irregularity (26.47% versus 47.50%, p = 0.02), and positive remodeling (40.00% versus 62.50%, p = 0.02). Over a median follow-up period of 32.5 months (Q1-Q3: 14.0-56.3 months), higher Lp(a) levels were linked to stroke recurrence risk (HR = 2.65; 95% CI: 1.28-5.47; p = 0.009). In a 4-group classification according to Lp(a) and plaque vulnerable features, patients with high Lp(a) and ≥ 2 vulnerable plaque features had the highest risk of stroke recurrence (45.5%; p = 0.004). Causal mediation analysis indicated that approximately 27.0% of the prognostic impact of Lp(a) was mediated through vulnerable plaque features.
conclusionElevated Lp(a) levels are linked to an increased stroke recurrence risk in sICAS patients, with part of this effect mediated by vulnerable plaque characteristics. KEY POINTS: Question Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease and plaque vulnerability, but the simultaneous evaluation of Lp(a) and vulnerable plaque features remains unknown. Findings Elevated Lp(a) levels are independently associated with vulnerable plaque features, all of which are linked to clinical outcomes. Clinical relevance This might offer novel targets to mitigate the atherogenic impact of Lp(a) and provide a clinically available, noninvasive tool for monitoring the clinical benefits of Lp(a)-lowering therapies in the future.
Indexed as
Identifiers
40522405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.